A 29-year-old pregnant woman with a history of anthracycline-induced clinical heart failure

Published on Jan 29, 2011in Health2.279
· DOI :10.4236/HEALTH.2011.31007
Valentina Scheggi1
Estimated H-index: 1
Fabio Mori1
Estimated H-index: 1
The number of women with heart disease who reach childbearing age in a good functional state increases continuously as advances in diagnosis and treatment improve overall health and prognosis. The cardiologist’s role is to give the woman an estimate of both maternal and fetal risk to allow her to make an informed decision about embarking on a pregnancy, and to provide appropriate antenatal care. There are only a few data about the natural history of anthracycline-induced cardiomyopathy during preg- nancy; we report our experience of a 29-year- old pregnant woman with a history of anthracycline-induced clinical heart failure.
📖 Papers frequently viewed together
#1Verena Stangl (MIT: Massachusetts Institute of Technology)H-Index: 50
#2Johanna Schad (MIT: Massachusetts Institute of Technology)H-Index: 1
Last. Karl Stangl (MIT: Massachusetts Institute of Technology)H-Index: 66
view all 6 authors...
Background: Maternal and neonatal complication rates are increased in pregnant women with heart disease. Cardiac risk assessment may be improved by defining low and high-risk groups. Aims: To analyze pregnancy risks in low and high-risk women with cardiovascular diseases. Methods and results: Pregnancy outcomes were analyzed in 93 consecutive women with heart disease, monitored in a single-centre cohort between 1996 and 2006. Women were classified according to pre-defined risk predictors as high...
#5Huib N. Caron (UvA: University of Amsterdam)H-Index: 42
Abstract The cumulative incidence of peripartum anthracycline-induced clinical heart failure (A-CHF) was evaluated in a cohort of 53 childhood cancer survivors who had delivered one or more children. None of them developed peripartum A-CHF (cumulative incidence 0%; 95% confidence interval (CI) 0–5.7%). The mean follow-up time after the first administration of anthracycline therapy was 20.3 years. They received a mean cumulative anthracycline dose of 267mg/m 2 . It is worth noticing that even 2 p...
Heart disease is the joint most common cause of maternal death in the UK.1 The most common cardiac causes of death involve cardiomyopathy and pulmonary hypertension (fig 1). Figure 1 Cardiac causes of maternal deaths in the UK: confidential enquiry into maternal deaths 1997–99 (total maternal deaths = 409, cardiac deaths = 41).1 Congenital heart disease (CHD) is infrequently associated with maternal death, but forms the greatest workload in a cardiac antenatal clinic and may be associated with s...
#1Samuel C. Siu (U of T: University of Toronto)H-Index: 37
#2Mathew SermerH-Index: 51
Last. Jack M. ColmanH-Index: 23
view all 3 authors...
Background The maternal and neonatal risks associated with pregnancy in women with heart disease receiving comprehensive prenatal care have not been well defined. Methods and Results We prospectively enrolled 562 consecutive pregnant women with heart disease and determined the outcomes of 599 pregnancies not ending in miscarriage. Pulmonary edema, arrhythmia, stroke, or cardiac death complicated 13% of pregnancies. Prior cardiac events or arrhythmia, poor functional class or cyanosis, left heart...
Either the mother or fetus may decompensate as a result of maternal heart disease, but available risk figures are based chiefly on retrospective studies or have focused on a particular cardiac disorder. This study prospectively enrolled 562 pregnant women with heart disease at 13 Canadian cardiac and obstetrical teaching hospitals. Pregnancies totaled 617. Women with congenital or acquired cardiac lesions or cardiac arrhythmia were eligible for the study. Follow-up assessments were made in the s...
Cited By1
#1Lori Chait-Rubinek (ND: University of Notre Dame)H-Index: 1
#2Justin A. Mariani (Alfred Hospital)H-Index: 23
Last. Belinda A. Campbell (Peter MacCallum Cancer Centre)H-Index: 16
view all 8 authors...
Long-term survivors of childhood, adolescent and young adult (AYA) malignancies with past exposure to potentially cardiotoxic treatments are at risk of peripartum cardiac dysfunction. Incidence and risk factors for peripartum cardiac dysfunction and maternal cardiac outcomes in this population were investigated. Eligible long-term survivors were aged <30 years at cancer diagnosis, with ≥1 pregnancy occurring ≥5 years after diagnosis. “Peripartum” cardiac events were defined as occurring within p...
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.